

# Long COVID: Exploring Advancements & Management

Avindra Nath, M.D.

Senior Investigator and Clinical Director – National Institute of Neurological Disorders and Stroke at the National Institute of Health

#### **Collaborators**







2



More resources available at: https://dchealth.dc.gov/dcrx



3

#### **Course Overview**

- This educational module is tailored for healthcare professionals seeking to deepen their understanding the emerging challenge of Long COVID.
- In order to receive completion credit, you must receive a passing score on the knowledge checks and complete the evaluation.
- This module will be approximately 60 minutes in length for viewing and completion of the evaluation.
- This module is approved for CME.



#### Instructors

#### Leonard H. Calabrese, DO

Professor of Medicine at the Cleveland Clinic Lerner College of Medicine

RJ Fasenmyer Chair of Clinical Immunology

Department of Rheumatic and Immunologic Disease Cleveland Clinic

Eric Wisotzky, MD

Medical Director, COVID Recovery Program

MedStar Health

### **Moderator/Advisor**

Avindra Nath, M.D.

Senior Investigator and Clinical Director at National Institute of Neurological Disorders and Stroke at the National Institute of Health



### **Conflict of Interest**

Dr. Calabrese is a speaker for, Amgen, UCB, GSK, Janssen, Sanofi, and AstraZeneca.
Dr. Wisotzky is a medical advisory board member for ImpediMed.
Dr. Nath has no financial disclosures or conflicts.
The course planners have no financial disclosures or conflicts.
All relevant financial relationships have been mitigated.

### **Anti-discrimination Policy**

The **instructors and advisor** have agreed to our anti-discrimination policy that prohibits the inclusion of discriminatory language, graphics, or references on the basis of race, gender identity, age, color, national origin, physical or mental disability, or religion.





# Long COVID: Advances in Case Definition, Diagnosis, and Pathogenesis

#### Leonard H. Calabrese

Professor of Medicine at the Cleveland Clinic Lerner College of Medicine

RJ Fasenmyer Chair of Clinical Immunology

Department of Rheumatic and Immunologic Disease Cleveland Clinic

#### **Learning Objectives**

- To describe the current case definitions used for Long COVID and their limitations in care and research
- To describe the pathophysiology, risks and protective factors for developing Long COVID
- To recognize common clinical manifestations of Long COVID
- To critically appraise the major therapies and evidence for Long COVID



### **Learning Objective #1**


To describe the current case definitions used for Long COVID and their limitations in care and research



Copyright 2024 DC Health | Government of the District of Columbia

### **COVID-19 Clinical Continuum**

- Sequela: A condition which is the consequence of a previous disease or injury
- Disease Course: Self limiting in 80%, Severe in 15-20%, Fatal in 1-2%



### Post Acute Sequelae of COVID-19 (PASC)

- Post COVID-19 condition occurs in individuals with a history of probable or confirmed SARS CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis:
  - CDC definition: 1 month
  - WHO definition: 3 months
- Common symptoms include fatigue, shortness of breath, cognitive dysfunction but also others and generally have an impact on everyday functioning.
- Symptoms may be:

  - New onset following initial recovery from an acute COVID-19 episode
  - Persisting from the initial illness
  - Fluctuating or relapsing over time



### **2024 NASEM Long COVID Definition**

#### • Long Covid (LC) manifests in multiple ways.

- A complete enumeration of possible signs, symptoms, and diagnosable conditions of LC would have hundreds of entries. Any organ system can be involved, and LC patients can present with:
  - Single or multiple symptoms, such as: shortness of breath, cough, persistent fatigue, post exertional malaise, difficulty concentrating, memory changes, recurring headache, lightheadedness, fast heart rate, sleep disturbance, problems with taste or smell, bloating, constipation, and diarrhea
  - Single or multiple diagnosable conditions such as: interstitial lung disease and hypoxemia, cardiovascular disease and arrhythmias, cognitive impairment, mood disorders, anxiety, migraine, stroke, blood clots, chronic kidney disease, postural orthostatic tachycardia syndrome (POTS) and other forms of dysautonomia, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), mast cell activation syndrome (MCAS), fibromyalgia, connective tissue diseases, hyperlipidemia, diabetes, and autoimmune disorders such as lupus, rheumatoid arthritis, and Sjogren's syndrome



### **Learning Objective #2**


To describe the pathophysiology, risks and protective factors for developing Long COVID



Copyright 2024 DC Health | Government of the District of Columbia

#### Long COVID at a Glance

- Symptoms:
  - Diversly affects multiple systems:
    - Respiratory
    - Nervous
    - Cardiovascular
    - Musculoskeletal



- Most common symptoms:
  - Fatigue
  - $\circ~$  Shortness of breath
  - $\circ$  Muscle pains
  - Chest pain
  - Brain fog
  - Headache
  - Depression




### **Documented Post COVID Pathologic Entities**

#### • Syndromic

- Persistent symptoms without defined pathology
- Long COVID "Long Haulers"
- Non-syndromic
  - Persistent symptoms secondary to defined pathology
  - Defined pathology without associated symptoms

#### Fig. 2: Extrapulmonary manifestations of COVID-19.


From: Extrapulmonary manifestations of COVID-19





#### **Household Pulse Survey**

Measuring Social and Economic Impacts During the Coronavirus Pandemic





US Census Bureau, 2023

### **Learning Objective #3**

To recognize common clinical manifestations of Long COVID



Copyright 2024 DC Health | Government of the District of Columbia

# Are There Risk Factors or Endotypes?



Copyright 2023 DC Health | Government of the District of Columbia

# **Risk Factors for Long COVID**

Observational study in a primary care population using data from Platform C19

#### Risk Predictors of Long COVID +

- Age ≥40 years
- Female sex
- Severity of acute COVID (symptom number burden), hospitalization
- Minority race, social determinants of health
- Frailty / Premorbid state of health

#### **Protective Mitigating Factors**

- Younger age\*
- Milder acute COVID-19 illness\*
- Vaccination decreases, but variable effect 15-50%) depending on study\*
- Previous infection (limited data)
- Omicron
- Use of antiviral therapy/metformin\*

\*Aggregate Summary of extant literature of which there are general agreement



Calabrese, 2023

# **Clinical Endotypes**

- Chronic fatigue
- Brain Fog
- Autonomic dysfunction
  - POTS
  - Dysrhythmias
- Pain Fibromyalgia
- Pulmonary pattern

All evaluations for possible Long COVID must begin with a rigorous assessment of defined underlying disorders, whether related or unrelated, that explain the patient's signs, symptoms, complaints, and concerns, and for which established therapies may exist.




#### **Fatigue Post COVID-19 Matrix**





# Study 1

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome is Common in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC): Results from a Post-COVID-19 Multidisciplinary Clinic





Bonilla, 2023

### **Post-Exertional Malaise (PEM)**

**Define:** A worsening of ME/CFS symptoms and/or the appearance of new symptoms after physical or cognitive exertion which was **previously tolerated**, and is often delayed 24-72 hours or more

#### Symptoms

• Fatigue/exhaustion, cognitive function, pain, flu like feeling, further exercise intolerance

### Triggers

• Physical activity, Mental activity, psychologic stressors, orthostatic



# Infections as Triggers for Chronic Pain

- Chronic pain as a result of COVID-19
- Well documented in epidemiologic studies, confounded by:
  - Psychological factors
  - Critical illness (ICU-related events)
- Exacerbation of chronic pain in the absence of actual infection
- New onset pain related to psychological stressors
- Epidemiologic studies reveal in Long COVID:
  - Pain in 11-90% of cases
  - Myalgia in 13-70% of cases
  - $\circ$  'Joint pain' in 5-55% of cases



J Pain D.J. Clauw et al. 161 (2020) 1694–1697


{Davis, 2021 } {Michelen, 2021 }{O'Mahoney, 2023 } Lopez-Leon, 2021 }{Natarajan, 2023

#### Long COVID and Impaired Cognition



Facts, data, and analytics about Covid and other biomedical matters.

#### **Long Covid and Cognitive Deficits**



gation leading to microthrombosis and fusion of neurons and glial cells, neuroinflammation and impaired neurogenesis, and low-serotonin-induced dysfunction in vagal signaling. CRH denotes corticotropin-releasing hormone.



Jastreboff, 2024

# Study 3

#### Sleep Disturbances are Highly Prevalent Among People with Long COVID

- 962 patients referred from ReCOver Clinic
- Assessed using PROMIS Sleep & select studies instruments
  - Scores standardized on T-scale (mean = 50, SD = 10)
  - $\circ$  Scores  $\geq$  60 indicate moderate disturbance
  - $\circ$  Scores  $\geq$  70 indicate severe disturbance

#### **Patient Characteristics**

Predominantly female (74.9%)Mean age: 49.6 years

#### Sleep Disturbance

- Mean T-score: 57.8 +/- 8.4
- 41% with moderate disturbances
- 8% reporting severe sleep disturbances
- Black race and hospitalization associated with greater sleep disturbances

#### Fatigue

- Mean T-score: 62.7 +/- (.1
- 67% with at least moderate fatigue
- 22% with severe fatigue



J Gen Intern Med . 2023 Jun;38(8):2015-2017. doi: 10.1007/s11606-023-08187-3. Epub 2023 Apr 4.

### **Learning Objective #4**


To critically appraise the major therapies and evidence for Long COVID



Copyright 2023 DC Health | Government of the District of Columbia

### Mechanisms That Could Underly Long COVID

- Predictors:
  - Female sex
  - $\circ$  Middle age
  - Diabetes
  - Obesity
  - Lower Sick Euthyroid Syndrome
  - HIV?





Peluso & Deeks Trends in Immunology 2022

#### Conclusion

- Long COVID is a Post Acute Infectious Sequelae (PAIS) that affects a significant portion of SARS CoV-2 infected patients.
- These sequelae can include both tissue based (pathologic) disorders (non-syndromic), but is more frequently present with an array of symptoms not readily explained based on classic tissue pathology dominated by fatigue, pain, neurocognitive dysfunction, breathlessness sleep disturbances as well as possibly numerous other complaints.
- Numerous pathogenic mechanisms have been proposed as contributing to both syndromic and non-syndromic Long COVID, though our current understanding remains incomplete.



Peluso & Deeks Trends in Immunology 2022

#### References

- 1. Landry, M., Bornstein, S., Nagaraj, N., Sardon, G. A., Castel, A., Vyas, A....Goldman, L. (2023). Postacute Sequelae of SARS-CoV-2 in University Setting. *Emerging Infectious Diseases*, 29(3), 519-527. https://doi.org/10.3201/eid2903.221522.
- 2. National Academies of Sciences, Engineering, and Medicine. 2024. A Long COVID Definition: A Chronic, Systemic Disease State with Profound Consequences. Washington, DC: The National Academies Press. https://doi.org/10.17226/27768.
- 3. Sudre CH, Antonelli M, Cheetham NJ, Molteni E, Canas LS, Bowyer V, Murray B, Rjoob K, Modat M, Capdevila Pujol J, Hu C, Wolf J, Spector TD, Hammers A, Steves CJ, Ourselin S, Duncan EL. Symptoms before and after COVID-19: a population and case-control study using prospective data. Eur Respir J. 2024 Apr 4:2301853. doi: 10.1183/13993003.01853-2023. Epub ahead of print. PMID: 38575161.
- 4. Lamers, M.M., Haagmans, B.L. SARS-CoV-2 pathogenesis. Nat Rev Microbiol 20, 270–284 (2022). https://doi.org/10.1038/s41579-022-00713-0
- 5. Panagiotakopoulos L, Godfrey M, Moulia DL, et al. Use of an Additional Updated 2023–2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices United States, 2024. MMWR Morb Mortal Wkly Rep 2024;73:377–381. DOI: <a href="http://dx.doi.org/10.15585/mmwr.mm7316a4">http://dx.doi.org/10.15585/mmwr.mm7316a4</a>.
- 6. Sudre, C.H., Murray, B., Varsavsky, T. et al. Attributes and predictors of long COVID. Nat Med 27, 626–631 (2021). https://doi.org/10.1038/s41591-021-01292-y
- 7. Gupta, A., Madhavan, M.V., Sehgal, K. et al. Extrapulmonary manifestations of COVID-19. Nat Med 26, 1017–1032 (2020). https://doi.org/10.1038/s41591-020-0968-3
- Bonilla, H., Quach, T. C., Tiwari, A., Bonilla, A. E., Miglis, M., Yang, P. C., Eggert, L. E., Sharifi, H., Horomanski, A., Subramanian, A., Smirnoff, L., Simpson, N., Halawi, H., Sum-Ping, O., Kalinowski, A., Patel, Z. M., Shafer, R. W., & Geng, L. N. (2023). Myalgic Encephalomyelitis/Chronic Fatigue Syndrome is common in post-acute sequelae of SARS-CoV-2 infection (PASC): Results from a post-COVID-19 multidisciplinary clinic. *Frontiers in neurology*, *14*, 1090747. <a href="https://doi.org/10.3389/fneur.2023.1090747">https://doi.org/10.3389/fneur.2023.1090747</a>
- 9. Cotler, J., Holtzman, C., Dudun, C., & Jason, L. A. (2018). A Brief Questionnaire to Assess Post-Exertional Malaise. Diagnostics (Basel, Switzerland), 8(3), 66. https://doi.org/10.3390/diagnostics8030066
- 10. Blitshteyn, S., Fedorowski, A. The risks of POTS after COVID-19 vaccination and SARS-CoV-2 infection: more studies are needed. *Nat Cardiovasc Res* 1, 1119–1120 (2022). https://doi.org/10.1038/s44161-022-00180-z
- 11. Clauw DJ, Häuser W, Cohen SP, Fitzcharles MA. Considering the potential for an increase in chronic pain after the COVID-19 pandemic. Pain. 2020 Aug;161(8):1694-1697. doi: 10.1097/j.pain.000000000001950. PMID: 32701829; PMCID: PMC7302093.
- 12. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, Redfield S, Austin JP, Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021 Aug; 38:101019. doi: 10.1016/j.eclinm.2021.101019. Epub 2021 Jul 15. PMID: 34308300; PMCID: PMC8280690.
- 13. Peluso, M. J., & Deeks, S. G. (2022). Early clues regarding the pathogenesis of long-COVID. Trends in immunology, 43(4), 268–270. https://doi.org/10.1016/j.it.2022.02.008





# Post Acute Sequelae of COVID-19 (Long COVID)

#### **Diagnostic Workup and Treatment**

Eric Wisotzky, MD, FAAPMR

Medical Director, COVID Recovery Program

MedStar Health

#### **Learning Objective**

- Review diagnostic workup and treatment options for various long COVID related symptoms including diagnostic workup of:
  - Neurologic/autonomic symptoms
  - Cardiovascular/pulmonary symptoms
  - Cognitive/mental health symptoms
  - ENT symptoms
  - Fatigue



#### American Academy of PM&R: National Call to Action

Mental Health Guidance Statement

Autonomic Dysfunction Guidance Statement

Cardiovascular Complications Guidance Statement

Breathing Discomfort Guidance Statement

Neurological Symptoms Guidance Statement

Pediatrics Guidance Statement

Cognitive Symptoms Guidance Statement

Fatigue Guidance Statement






Copyright 2023 DC Health | Government of the District of Columbia



# **Neurologic/Autonomic Symptoms**

#### **Neurologic Symptoms**

Multidisciplinary Collaborative Consensus Guidance Statement on the Assessment and treatment of Neurologic Sequelae in Patients with Post Acute Sequelae of SARS-CoV-2 infection (PASC)



Gaillard F., Radiopaedia, 2008



Melamed et.al., PM&R., 2023

### **Neurologic Symptoms: Diagnostic Workup**

- Symptom epidemiology
  - Headache in 21.5% of non-hospitalized patients, 2 months after illness
- Diagnostic Workup

#### Headache:

- $\circ\,$  Consider brain MRI
- Fundus exam for papilledema
- Cerebral venous thrombosis is of concern in this population which can manifest as headaches

#### **Neuropathy:**

- Consider appropriate laboratory workup (r/o preexisting diabetes)
- Consider electrodiagnostic studies
- Usually, small fiber so may need skin biopsy



Bell ML et al., PONE, 2021

# **Neurologic Symptoms: Treatment**

### • Headache:

- Tension-Type: acetaminophen, aspirin, non-steroidal anti-inflammatory drugs (NSAIDs)
- Migraine: acetaminophen, NSAIDs, tricyclic antidepressants (TCAs), topiramate, triptans, gepants/calcitonin gene-related peptide (CRG) antagonists
- Neurology referral if refractory

### • Neuropathy:

- Physical/occupational therapy
- $\ensuremath{\circ}$  Assistive device
- $\,\circ\,$  Medications for neuropathic pain



### **Autonomic Symptoms**

Multi-disciplinary Collaborative Consensus Guidance Statement on the Assessment and Treatment of Autonomic Dysfunction in Patients with Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)



Saint Luke's, 2024



Blitshteyn S. et al., PM&R., 2022

### **Autonomic Symptoms and Diagnostic Workup**

### • Symptoms

- Dizziness, Syncope, Fatigue
  - Some of these symptoms could be autonomic, vestibular, or other causes

### • Diagnostic Workup

- Postural Orthostatic Tachycardia Syndrome (POTS):
  - Sustained HR increase ≥30 bpm within 10 min for adults (≥40 bpm for adolescents 12– 19 years of age) of standing or on tilt table
  - Absence of orthostatic hypotension
  - Symptoms of orthostatic intolerance for  $\geq 6$  months
- Orthostatic Hypotension:
  - Sustained drop in blood pressure  $\geq 20/10$  mm Hg within 3 min of standing or on tilt table



# **Autonomic Symptoms and Diagnostic Workup Continued**

### • Labs:

- Complete Blood Count (CBC)
- Complete Metabolic Panel (CMP)
- Thyroid Function Test (TFT)
- Vitamin B12
- Ferritin
- Morning cortisol
- Antinuclear Antibody (ANA), Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP)
- Cardiac workup: to be discussed later
- Vestibular evaluation: ENT, Vestibular Physical Therapist



### Autonomic Symptoms: Non-Pharmacologic Treatment

- >3 Liters of fluid per day
- >10 grams of salt per day (4 mg of sodium)
- Compression garments
- Personalized autonomic rehabilitation program
- Deep breathing exercises



### **Autonomic Symptoms: Pharmacologic Treatment**

### First line:

- Beta-blockers
- Fludrocortisone
- Midodrine

### Second line:

- Pyridostigmine
- Ivabradine
- Clonidine
- Methyldopa
- Modafinil
- Methylphenidate
- SSRIs/SNRIs




# Cardiovascular/Pulmonary Symptoms



Copyright 2023 DC Health | Government of the District of Columbia

### **Cardiovascular Symptoms**

Multi-disciplinary Collaborative Consensus Guidance Statement on the Assessment and Treatment of Cardiovascular Complications in Patients with Post-Acute Sequelae of Sars-CoV-2 Infection (PASC)





Whiteson JH et al., PM&R., 2022

Copyright 2023 DC Health | Government of the District of Columbia

# **Cardiovascular Symptoms**

- Chest pain
  - Prevalence ranges from 10-20%
  - o Differential diagnosis (DDx): Cardiac, pulm, MSK, GI
- Palpitations
  - $\circ~$  Prevalence up to 10%
  - $\circ~$  Heightened sense of awareness of heartbeat
  - May be persistent or transient
  - $\,\circ\,$  With rest or activity
- Fatigue
- Dyspnea
- Dizziness



# **Cardiovascular Symptoms: Diagnostic Workup**

- For more urgently concerning symptoms consider:
  - EKG
  - Echocardiogram
  - CTA chest
- Labs:
  - CBC
  - Basic Metabolic Panel (BMP)
  - Troponin
  - Brain Natriuretic Peptide (BNP)
  - D-dimer
  - CRP/ESR



### **Cardiovascular Symptoms: Diagnostic Workup**

- Palpitations
  - $\circ\,\mathsf{EKG}$
  - $\circ$  Echocardiogram
  - $\circ$  Holter monitor
- Chest pain
  - $\odot$  Similar to above
  - $\odot$  Consider stress test




### **Cardiovascular Symptoms: Treatment**

- Palpitations:
  - Antiarrhythmic drugs
- POTS symptoms (see autonomic symptoms above)
- Cardiac rehabilitation
- Chest pain of musculoskeletal origin
  - $\,\circ\,$  Anti-inflammatories
  - Physical therapy



## **Pulmonary Symptoms**

Multi-disciplinary Collaborative Consensus Guidance Statement on the Assessment and Treatment of Breathing Discomfort and Respiratory Sequelae in Patients with Post-Acute Sequelae of Sars-CoV-2 Infection (PASC)





Maley JH et al., PM&R., 2022

Copyright 2023 DC Health | Government of the District of Columbia

# **Pulmonary Symptoms: Diagnostic Workup**

- Pulse oximetry
- Pulmonary function tests
- Chest imaging
- Echocardiogram
- Stress test



# **Pulmonary Symptoms: Treatment**

- Oxygen (as indicated)
- Pulmonary rehabilitation
- Breathing exercises
- Medications:
  - $\,\circ\,$  Oral or inhaled corticosteroids
  - $\circ$  Inhaled bronchodilators
  - $\circ$  Montelukast




# DC HEALTH GOVERNMENT OF THE DISTRICT OF COLUMBIA

# **Cognitive/Mental Health Symptoms**

Copyright 2023 DC Health | Government of the District of Columbia

### **Cognitive Symptoms**

Multi-disciplinary Collaborative Consensus Guidance Statement on the Assessment and Treatment of Cognitive Symptoms in Patients with Post-Acute Sequelae of Sars-CoV-2 Infection (PASC)



Budson, Harvard Health Publishing, 2021



Fine JS et al., PM&R., 2022

# **COVID-19 and Alzheimer's Study**

### **Association of COVID-19 with New Onset Alzheimer's Disease**

- Retrospective cohort study of 6,245,282 older adults (age ≥65 years) with COVID-19
  - At significantly increased risk for new diagnosis of Alzheimer's disease within 360 days after the initial COVID-19 diagnosis
    - Especially in people age ≥85 years and in women



Wang L et al., Journal of Alzheimer's Disease. 2022

# **Cognitive Symptoms: Diagnostic Workup**

- **Symptoms**: 30.8% of non-hospitalized patients, 2 months after illness
- Diagnostic Workup
  - Cognitive screen (MOCA, MMSE)
  - Neuropsychology testing
  - Lab workup:
    - $\circ$  CBC
    - $\circ$  Vitamin B12
    - Thiamine/Folate
    - Homocysteine
    - Vitamin D
    - Magnesium
    - o Liver function tests
    - Thyroid testing



Bell ML et al., PLoS One. 2021

# **Cognitive Symptoms: Treatment**

- Sleep assessment/treatment
- Mood assessment/treatment
- Speech language pathologist (cognitive rehabilitation)
- Structured return to physical activity
- Medications *could* be considered:
  - Guanfacine with N-acetyl cysteine (NAC)
  - Stimulants: modafanil, methylphenidate, etc.



### **Mental Health Symptoms**

Multi-disciplinary Collaborative Consensus Guidance Statement on the Assessment and Treatment of Mental Health Symptoms in Patients with Post-Acute Sequelae of Sars-CoV-2 Infection (PASC)



NCBHS, 2024



Cheng AL et al., PM&R, 2023

### **COVID-19 and Anxiety Meta-Analysis**

Mid and Long-term Neurological and Neuropsychiatric Manifestations of Post-COVID-19 Syndrome

• Meta-analysis found that approximately 23% of participants reported experiencing anxiety 3 months or more after a COVID-19 infection



Premraj L et al., Journal of the Neurological Sciences. 2022

# Mental Health Symptoms: Diagnostic Workup

- Symptom screens
  - Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder 7 (GAD-7), etc.
- Comprehensive patient history



# Mental Health Symptoms: Treatment

- Referrals:
  - Supportive psychotherapy
  - Psychiatry
  - Cognitive behavioral therapy
- Medications
  - $\odot\,\text{SSRIs}$  or SNRIs






# **ENT Symptoms**

### **ENT Symptoms**


- Loss of taste/smell
- Dizziness/vertigo (vestibular)





### **ENT Symptoms: Diagnostic Workup**

- Rhinoscopy
- Imaging of sinuses
- Vestibular evaluation



Rogalskyi V., Radiopaedia 2024



### **ENT Symptoms: Treatment**

- Antihistamines
- Intranasal corticosteroids
- Smell training
- Vestibular rehabilitation



Galper, NY Institute of Aromatherapy, 2021





# Fatigue

Copyright 2023 DC Health | Government of the District of Columbia

# Fatigue

Multi-disciplinary Collaborative Consensus Guidance Statement on the Assessment and Treatment of Fatigue in Post-Acute Sequelae of Sars-CoV-2 Infection (PASC)



O'Connell, Healthline, 2023



Herrera JE et al., PM & R. 2021

# Fatigue

- Frequency: 37.5% of non-hospitalized patients, 2 months after illness
- Etiology: multifactorial
- Presentation: central or peripheral
  - Post-exertional malaise (PEM)



Bell ML, PLoS One. 2021

# **Fatigue: Diagnostic Workup**

- Detailed history and physical exam
  - o Sleep --> consider sleep apnea!

 $\circ$  Mood

○ Cardiopulmonary

 $\circ$  Medications

• Labs:

 $\circ$  CBC

 $\circ$  CMP

• Thyroid-Stimulating Hormone (TSH)

 $\circ$  CRP

• Creatine Kinase (CK)

• Consider functional assessment (6 min walk test)



### **Fatigue: Treatment**

- Slow return to activity
- Energy conservation
- Pharmacologic treatment
- Pacing
  - Rate the intensity of most significant symptoms (e.g., fatigue, headache) from 1 to 10 prior to beginning a task, and use this scale to decide when symptoms worsen, and it is time for a break.
  - When symptom severity increases by three units (e.g., increased from a 2 to a 5) it is moment to take a break.
  - Focus on decreasing the symptom (e.g., for headaches take medication; for fatigue lay down, practice relaxation exercises).
  - When the symptom has decreased to its initial baseline, continue your activity.
  - $\circ\,$  Repeat as needed throughout the day.



### **Fatigue: Treatment**

### Phased return to physical activity

Minimum of 7 days at each phase Drop back		a phase if finding it difficult	Only move up when progression criteria are met	
Phase 1 Goal: preparation for return to exercise Exercise: rest, breathing exercises, flexibility/ stretching, balance, gentle walking Suggested Rating of Perceived Exertion (RPE): 6-8	Phase 2 Goal: low intensity activity such as walking and light yoga, and light household/ garden tasks Exercise: graduated increases by 10-15 mins/ day Suggested RPE: 6-11 Progression: 7 days and when can walk 30 minutes at RPE 11	Phase 3 Goal: moderate intensity aerobic and strength challenge Exercise: an example would be 2 intervals of 5 minute aerobic exercise separated by 1 block of recovery. Add one interval per day as tolerated Suggested RPE: 12-14 Progression: 7 days and when can achieve 30 minute session, and feel	Phase 4 Goal: moderate intensity aerobic and strength challenge with co-ordination and functioning skills Exercise: 2:1 days training: recovery Suggested RPE: 12-14 Progression: 7 days and when fatigue levels are normal	Phase 5 Goal: baseline exercise Exercise: return to regular exercise pattern Suggested RPE: >15 as tolerated

Only exercise if: you feel recovered from the previous day, no new, or return of, symptoms Spend at least a few minutes warming up and cooling down at the beginning and end of a session respectively

recovered after an hour

Any abnormal shortness of breath for a given activity level, or return of symptoms including temperature, lethargy or chest pain

Seek medical advice

Monitor your mood. If you feel more anxious, down or low, speak to someone, and seek medical advice if you are concerned

### Borg Rating of Perceived Exertion (RPE) No exertion 14

- 6 No exertion
- 7 Extremely light
- 8 9 Very light 10
- 11 Light
- 12 Light
- 13 Somewhat hard

- 15 Hard (heavy)
  - 16
  - 17 Very hard
  - 18
  - 19 Extremely hard
  - 20 Maximal exertion

omewhat hard



Salman et al., BMJ, 2021

# **Future Directions for Treatment**

- Paxlovid
- Metformin
- Low dose naltrexone
- Intravenous Immunoglobulin (IVIG)
- Hyperbaric oxygen
- Stellate ganglion block
- Nicotine patch



# Summary

- Long COVID can present with a myriad of symptoms
- There is no single well-established treatment for underlying pathophysiology to this point
- Appropriate medical workup should be considered based on presenting symptoms
- There are many available supportive treatments for various symptoms
- Hope for future directions in care



### References

- 1. Melamed E, Rydberg L, Ambrose AF, et al. Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of neurologic sequelae in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM&R. 2023; 1-23. doi:10.1002/pmrj.12976
- Bell, M. L., Catalfamo, C. J., Farland, L. V., Ernst, K. C., Jacobs, E. T., Klimentidis, Y. C., Jehn, M., & Pogreba-Brown, K. (2021). Post-acute sequelae of COVID-19 in a non-hospitalized cohort: Results from the Arizona CoVHORT. *PloS one*, *16*(8), e0254347. <u>https://doi.org/10.1371/journal.pone.0254347</u>
- 3. Blitshteyn, S., Whiteson, J. H., Abramoff, B., Azola, A., Bartels, M. N., Bhavaraju-Sanka, R., Chung, T., Fleming, T. K., Henning, E., Miglis, M. G., Sampsel, S., Silver, J. K., Tosto, J., Verduzco-Gutierrez, M., & Putrino, D. (2022). Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of autonomic dysfunction in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). *PM & R : the journal of injury, function, and rehabilitation, 14*(10), 1270–1291. <u>https://doi.org/10.1002/pmrj.12894</u>
- 4. Whiteson, J. H., Azola, A., Barry, J. T., Bartels, M. N., Blitshteyn, S., Fleming, T. K., McCauley, M. D., Neal, J. D., Pillarisetti, J., Sampsel, S., Silver, J. K., Terzic, C. M., Tosto, J., Verduzco-Gutierrez, M., & Putrino, D. (2022). Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of cardiovascular complications in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). *PM & R : the journal of injury, function, and rehabilitation, 14*(7), 855–878. <a href="https://doi.org/10.1002/pmrj.12859">https://doi.org/10.1002/pmrj.12859</a>
- 5. Maley, J. H., Alba, G. A., Barry, J. T., Bartels, M. N., Fleming, T. K., Oleson, C. V., Rydberg, L., Sampsel, S., Silver, J. K., Sipes, S., Verduzco-Gutierrez, M., Wood, J., Zibrak, J. D., & Whiteson, J. (2022). Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of breathing discomfort and respiratory sequelae in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). *PM & R : the journal of injury, function, and rehabilitation, 14*(1), 77–95. <u>https://doi.org/10.1002/pmrj.12744</u>
- 6. Fine JS, Ambrose AF, Didehbani N, et al. Multi-disciplinary collaborativeconsensus guidance statement on theassessment and treatment of cognitivesymptoms in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM&R. 2022;14(1):96-111. doi:10.1002/pmrj.12745108 CONSENSUS GUIDANCE STATEMENT ON PASC COG NITIVE SYMPTOMS



### References

- 7. Wang, Lindsey et al. 'Association of COVID-19 with New-Onset Alzheimer's Disease'. Journal of Alzheimer's Disease. 2022;89(2):411-414. doi: 10.3233/JAD-220717
- 8. Cheng, A. L., Anderson, J., Didehbani, N., Fine, J. S., Fleming, T. K., Karnik, R., Longo, M., Ng, R., Re'em, Y., Sampsel, S., Shulman, J., Silver, J. K., Twaite, J., Verduzco-Gutierrez, M., & Kurylo, M. (2023). Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of mental health symptoms in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). *PM & R : the journal of injury, function, and rehabilitation*, *15*(12), 1588–1604. <u>https://doi.org/10.1002/pmrj.13085</u>
- 9. Premraj, L., Kannapadi, N. V., Briggs, J., Seal, S. M., Battaglini, D., Fanning, J., Suen, J., Robba, C., Fraser, J., & Cho, S. M. (2022). Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis. *Journal of the neurological sciences*, 434, 120162. <u>https://doi.org/10.1016/j.jns.2022.120162</u>
- 10. Herrera, J. E., Niehaus, W. N., Whiteson, J., Azola, A., Baratta, J. M., Fleming, T. K., Kim, S. Y., Naqvi, H., Sampsel, S., Silver, J. K., Verduzco-Gutierrez, M., Maley, J., Herman, E., & Abramoff, B. (2021). Multidisciplinary collaborative consensus guidance statement on the assessment and treatment of fatigue in postacute sequelae of SARS-CoV-2 infection (PASC) patients. *PM & R : the journal of injury, function, and rehabilitation, 13*(9), 1027–1043. <u>https://doi.org/10.1002/pmrj.12684</u>
- 11. Salman, D., Vishnubala, D., Le Feuvre, P., Beaney, T., Korgaonkar, J., Majeed, A., & McGregor, A. H. (2021). Returning to physical activity after covid-19. *BMJ (Clinical research ed.)*, 372, m4721. <u>https://doi.org/10.1136/bmj.m4721</u>



# DC HEALTH

### GOVERNMENT OF THE DISTRICT OF COLUMBIA

899 North Capitol Street NE, 5th Fl, Washington, DC 20002

